T-cell function after interleukin-2 therapy in HIV-infected patients is correlated with serum cortisol concentrations

AIDS

Volumn 18, Issue 15, 2004, Pages 2001-2007

  Lindemann, Monika ^a   Witzke, Oliver ^a   Winterhagen, Toni ^a   Ross, Birgit ^a   Kreuzfelder, Ernst ^a   Reinhardt, Walter ^a   Roggendorf, Michael ^a   Mann, Klaus ^a   Philipp, Thomas ^a   Grosse Wilde, Hans ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Antigen; CD4 cell count; Cortisol; HIV; Interleukin 2; Lymphocyte proliferation; Mitogen

Indexed keywords

ANTIEMETIC AGENT; CD4 ANTIGEN; CORTICOTROPIN RELEASING FACTOR; DIPYRONE; HYDROCORTISONE; INTERLEUKIN 2; MITOGENIC AGENT; PARACETAMOL; PROTEINASE INHIBITOR; RECOMBINANT INTERLEUKIN 2; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCORTISONE BLOOD LEVEL; IN VITRO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE TRANSFORMATION TEST; MALAISE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE;

ADULT; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; HYDROCORTISONE; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; T-LYMPHOCYTES; VIRAL LOAD;

EID: 7744241504     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200410210-00004     Document Type: Article

References (24)

1. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT, Falloon J, et al. Increases in CD4-T-lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 1995; 332:567-575.
2. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT, Walker RE, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996; 335:1350-1356.
3. Hengge UR, Goos M, Esser S, Exner V, Dotterer H, Wiehler H, et al. Randomized controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS 1998; 12:225-234.
4. Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, et al. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS 2003; 17:343-351.
5. Aladdin H, Larsen CS, Moller BK, Ullum H, Buhl MR, Gerstoft J, et al. Effects of subcutaneous interleukin-2 therapy on phenotype and function of peripheral blood mononuclear cells in human immunodeficiency virus infected patients. Scand J Immunol 2000; 51:168-175.
6. Valdez H, Mitsuyasu R, Landay A, Sevin AD, Chan ES, Spritzer J, et al. Interleukin-2 increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J Infect Dis 2003; 187:320-325.
7. Kelleher AD, Roggensack M, Emery S, Carr A, French MA, Cooper DA. Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens. Clin Exp Immunol 1998; 113:85-91.
8. Ades EW, Bosse D, Orr S, Gillespie T. Immune responses in humans while receiving adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells: acute anergy to mitogens and recall antigens. Pathobiology 1990; 58:78-83.
9. Wiebke EA, Rosenberg SA, Lotze MT. Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. J Clin Oncol 1988; 6:1440-1449.
10. Witzke O, Winterhagen T, Kribben A, Philipp Th, Mann K, Reinhardt W. Interleukin-2 given to asymptomatic HIV-infected individuals leads to an exaggerated response of the pituitary gland to the action of CRH. Clin Endocrinol 2003; 59:104-109.
11. Witzke O, Winterhagen T, Reinhardt W, Heemann U, Grosse-Wilde H, Kreuzfelder E, et al. Comparison between subcutaneous and intravenous interleukin-2 treatment in HIV disease. J Intern Med. 1998; 244:235-240.
12. Lindemann M, Virchow S, Ramann F, Barsegian V, Kreuzfelder E, Siffert M, et al. The G protein β3 subunit 825T allele is a genetic marker for enhanced T cell response. FEBS Letters 2001; 495:82-86.
13. Lindemann M, Böhmer J, Zabel M, Grosse-Wilde H. ELISpot: a new tool for the detection of nickel sensitization. Clin Exp Allergy 2003; 33:992-998.
14. Mayo J, Collazos J, Martinez E, Ibarra S. Adrenal function in the human immunodeficiency virus-infected patient. Arch Intern Med 2002; 162:1095-1098.
15. Hoshino Y, Yamashita N, Nakamura T, Iwamoto A. Prospective examination of adrenocortical function in advanced AIDS patients. Endocrine J 2002; 49:641-647.
16. Lortholary O, Christeff N, Casassus P, Thobie N, Veyssier P, Tregoff P, et al. Hypothalamo-pituitary-adrenal function in human immunodeficiency virus-infected men. J Clin Endocrinol Metab 1996; 81:791-796.
17. Jefferies WM. Cortisol and immunity. Med Hypothesis 1991; 34:198-208.
18. Spink WW. Adrenocortical steroids in the management of selected patients with infectious disease. Ann Intern Med 1960; 53:1-32.
19. Briegel J. Cortisol in critically ill patients with sepsis: physiologic functions and therapeutic implications. Wien Klin Wochenschr 2000; 112:341-352.
20. Kilger E, Weis F, Briegel J, Frey L, Goetz AE, Reuter D, et al. Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery. Crit Care Med 2003; 31:1068-1074.
21. Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Volk HD, et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Clin Care Med 2003; 167:512-520.
22. Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med 2002; 165:983-991.
23. Teppler H, Kaplan G, Smith KA, Cameron P, Montana A, Meyen P, et al. Efficacy of low doses of polyethylene glycol derivate of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. J Infect Dis 1993; 167:291-298.
24. Teppler H, Kaplan G, Smith KA, Montana AL, Meyn P, Cohn ZA. Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection. J Exp Med 1993; 177:483-492.